Human papillomavirus (HPV) E6 and E7 oncogenes are expressed in the great majority of human cervical carcinomas, whereas the viral E2 regulatory gene is usually disrupted in these cancers. To investigate the roles of the papillomavirus E2 genes in the development and maintenance of cervical carcinoma, the bovine papillomavirus (BPV) E2 gene was acutely introduced into cervical carcinoma cell lines by infection with high-titer stocks of simian virus 40-based recombinant viruses. Expression of the BPV E2 protein in HeLa, C-41, and MS751 cells results in specific inhibition of the expression of the resident HPV type 18 (HPV18) E6 and E7 genes and in inhibition of cell growth. HeLa cells, in which HPV gene expression is nearly completely abolished, undergo a dramatic and rapid inhibition of proliferation, which appears to be largely a consequence of a block in progression from the G1 to the S phase of the cell cycle. Loss of HPV18 gene expression in HeLa cells is also accompanied by a marked increase in the level of the cellular p53 tumor suppressor protein, apparently as a consequence of abrogation of HPV18 E6-mediated destabilization of p53. The proliferation of HT-3 cells, a human cervical carcinoma cell line devoid of detectable HPV DNA, is also inhibited by E2 expression, whereas two other epithelial cell lines that do not contain HPV DNA are not inhibited. Thus, a number of cervical carcinoma cell lines are remarkably sensitive to growth inhibition by the E2 protein.
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Although BPV E2-mediated inhibition of HPV18 E6 and E7 expression may contribute to growth inhibition in some of the cervical carcinoma cell lines, the BPV E2 protein also appears to exert a growth-inhibitory effect that is independent of its effects on HPV gene expression.
Specific types of human papillomaviruses (HPV) are leading candidates for the infectious agents involved in the development of human cervical carcinoma (39, 71) . The great majority of cervical carcinomas contain and express the E6 and E7 genes of HPV types 16 and 18 (HPV16 and HPV18; the high-risk virus types) (1, 2, 7, 18, 31, 40, 50, 52, 53, 57, 70) . These same viral genes can immortalize or transform cultured epithelial cells, including human cervical epithelial cells (16, 41, 42, 67, 68) . The HPV16 and HPV18 E6 and E7 proteins bind to the cellular tumor suppressor proteins p53 and p105 , respectively, and are thought to inactivate these growth-inhibitory proteins (19, 21, 30, 38, 49, 66) . In contrast, the E6 and E7 proteins of HPV types that are infrequently detected in cervical carcinoma tissue display much lower ability to transform cells or bind these cellular proteins. Furthermore, the rare cervical carcinoma cell lines that are devoid of HPV DNA often contain mutant p53 and p105RB genes, whereas these genes appear wild type in carcinoma cell lines that contain viral DNA (11, 12, 48, 69) . These findings strongly suggest that the interaction between HPV16 and HPV18 E6 and E7 proteins and cellular tumor suppressor proteins plays a causal role in the development of human cervical carcinoma.
Most benign HPV-induced cervical lesions do not progress to carcinoma, and the molecular mechanisms underlying progression are not well understood. (18, 33, 51, 56) . The frequent loss of a functional E2 gene during malignant progression led to the suggestion that inactivation of this gene may play a role in this progression (10, 45, 51, 62) . The E2 gene encodes site-specific DNA-binding proteins that stimulate or inhibit transcription, depending on the particular E2 protein synthesized and on the position of the E2 binding sites relative to other transcriptional control elements (26, 34) . Cotransfection and in vitro transcription studies indicate that full-length bovine papillomavirus (BPV) E2 protein inhibits transcription of genes under the control of the HPV18 P,05 and HPV16 P97 promoters, which normally direct transcription of the E6 and E7 genes, by binding to sites located within the promoters and interfering with the binding of essential transcription factors (17, 22, 46, (60) (61) (62) . The HPV16 and HPV18 E2 proteins bind to the same consensus DNA recognition sequence as does the BPV E2 protein and exert a similar inhibitory effect on HPV transcription, although they appear to be less potent repressors than the BPV protein (5, 6) . Moreover, introduction of the HPV18 E2 gene by transfection also appeared to inhibit expression of the E6 and E7 genes in HPV-immortalized human foreskin keratinocytes (47 High-titer stocks of recombinant viruses were prepared essentially as described previously (54) . Briefly, recombinant viral DNA was excised from the bacterial plasmid vector by EcoRI digestion, recircularized with DNA ligase in vitro, and transfected into CMT4 cells that were subsequently treated with heavy metals to induce expression of SV40 large T antigen (23) . Stocks were serially passaged when significant cytopathic effect occurred. Wild-type Paval and mutant viruses containing the following previously described mutations were prepared: E2aml (nonsense mutation in the 5' portion of the E2 gene) (54), E5d29 (frameshift mutation in the E5 gene) (52), E4aml (nonsense mutation in the E4 gene) (55) , E2-RMC1 (mutation that eliminates the initiating methionine codon for the 3' E2TR gene) (44) , and E2-BMV (mutation that deletes the DNA binding domain common to the full-length E2 protein and to E2TR) (55) . For viruses expressing an intact E2 gene, titers were estimated by measuring E2-mediated transactivation in NL3D cells as described previously (54, 55 45 ,ul of Laemmli SDS-polyacrylamide gel electrophoresis sample buffer. After boiling for 5 min, the samples were electrophoresed through a 17% polyacrylamide gel. The gel was dried and processed for fluorography using Amplify (Amersham). To detect the cellular p53 protein, cells were labeled for 3 or 4 h. Extracts were prepared and analyzed as described above except that 0.8 p.1 of a 1:3 dilution of anti-p53 antiserum CM-1 (Novocastra Laboratories Ltd., Newcastle upon Tyne, United Kingdom) was used for immunoprecipitation per 106 cpm. The amount of p53 immunoprecipitated was assessed by using a PhosphorImager (Molecular Dynamics, Inc.) and Imagequant software.
RNA analysis. Two days after plating, cervical carcinoma cells in 6-cm-diameter plates were infected at high multiplicity with Paval or Pava-BMV. Approximately 70 h after infection, total cellular RNA was harvested and quantitated spectrophotometrically (9) . Aliquots (10 ,ug) of total RNA were denatured, electrophoresed on an agarose gel containing formaldehyde, and transferred to nitrocellulose. HPV18 E6/E7 message was detected by hybridization to a 32p_ labeled probe extending from HPV18 nucleotides 7582 to 1128 (20) . After autoradiography, blots were stripped by incubation at 65°C in 2 mM Tris HCl (pH 8.2)-i mM EDTA-0.1% SDS and rehybridized to a radiolabeled human -y-actin gene (25) .
Plating assays. HeLa cells (104) were plated in 1.5-cmdiameter wells 2 days prior to infection. Two days after high-multiplicity infection with virus, cells were trypsinized and 104 cells were plated in 6-cm-diameter plastic plates or in 0.3% agarose containing DMEM with 10% fetal calf serum. Cells were fed with fresh medium or agarose every 4 days. One week after plating, photographs were taken with an Olympus OM-2S camera and 451F550 yellow filter attached to an Olympus CK-2 phase-contrast inverted microscope.
Thymidine incorporation assay of DNA synthesis. Cells were plated in 1. (4) by incubation at 4°C with 1 ml of a solution containing 0.005% propidium iodide (Sigma Co., St. Louis, Mo.), 2 mM sodium citrate, 0.002 RNase (Worthington Biochemical, Freehold, N.J.), 0.2% Triton X-100, and 0.5% Nonidet P-40. The nuclei were analyzed on a EPICS Profile flow cytometer (Coulter Electronics, Hialeah, Fla.). Cell cycle distribution was evaluated by using the software Verity Modfit (Verity Software House, Topsam, Maine). The fraction of cells in S phase was evaluated by using a second-degree polynomial.
RESULTS
For the experiments reported here, the following human cervical carcinoma cell lines were used: HeLa, MS751, and C-4I, all of which contain HPV18 DNA; SiHa and CaSki, which contain HPV16 DNA; and C33a and HT-3, which are devoid of HPV DNA (40, 70) . We also analyzed CV-1 monkey kidney epithelial cells and A431 human epidermoid carcinoma cells. The BPV E2 gene was delivered into these cell lines by high-multiplicity infection with a replicationdefective BPV-SV40 recombinant virus, Paval, and its derivatives (54, 55) . This recombinant virus also contains the BPV E4 and E5 genes, but these genes are not required for the growth-inhibitory effect in HeLa cells described below (see Fig. 7 infection and subjected to Northern analysis using probes specific for the HPV18 E6/E7 region. As shown in Fig. 2A (Fig. 2B) , indicating that inhibition of HPV gene expression was not due to a generalized inhibition of transcription. Thus, expression of the BPV E2 gene efficiently represses expression of the resident HPV genomes in cervical carcinoma cell lines.
The E6 proteins of the high-risk HPV types target the cellular tumor suppressor protein p53 for rapid degradation in vitro, and the levels of p53 are low in HeLa cells and in E6-expressing keratinocyte cell lines, presumably as a consequence of this pathway (28, 30, 32, 47) . To investigate whether BPV E2 expression and reduction in HPV18 E6 expression affect the level of p53 in HeLa cells, we measured p53 levels in uninfected HeLa cells, which express the HPV18 E6 protein, and in cells infected with Paval, in which the BPV E2 protein represses expression of the HPV18 E6 gene (Fig. 3) 3 and 4) . These results demonstrate a reciprocal correlation between HPV18 E6 and p53 expres- Proteins in the immunoprecipitate were subjected to SDS-polyacrylamide gel electrophoresis and autoradiography. The arrowhead marks the position of p53. On some gels, the HeLa cell p53 resolves into two bands of similar electrophoretic mobility, as has been described for p53 synthesized in vitro from HeLa cell RNA (30) . sion in HeLa cells and suggest that E6-mediated p53 destabilization is responsible for the low amount of cellular p53 in these cells.
To determine the effect of BPV1 E2 expression on cell proliferation, HeLa cell growth was assessed in plating assays. Two days after mock infection or infection with Paval, HeLa cells were passaged, and their ability to form colonies on plastic or in agarose was determined. Uninfected HeLa cells efficiently formed large colonies on plastic or in agarose ( Fig. 4A and C) . In contrast, colony formation by HeLa cells was markedly inhibited by infection with the virus that expresses the wild-type E2 gene ( Fig. 4B and D) . The growth-inhibited HeLa cells assumed a more extended appearance and remained metabolically active as assessed by trypan blue exclusion. In these and similar experiments, infection with the wild-type virus caused an approximately 25-fold reduction in the number of macroscopic colonies that developed. The small number of Paval-infected HeLa cells that formed colonies on plastic were not genetically resistant to infection or growth inhibition; cell lines derived from individual colonies that developed after infection are growth inhibited upon reinfection with E2-expressing virus. Evidently, at the time of initial infection, these cells did not express sufficient levels of E2 protein for growth inhibition or were transiently refractory to its effects.
The effect of BPV E2 expression was also determined in short-term DNA synthesis assays in which incorporation of
[3H]thymidine into cellular DNA was assessed by measuring acid-insoluble radioactivity 2 to 3 days after infection. As shown in Table 1 , infection with the virus expressing the wild-type E2 gene, but not the mutant E2 gene, caused a marked (>95%) decrease in HeLa cell DNA synthesis, in accord with the reduction in colony formation described above. E2-dependent inhibition of cellular DNA synthesis was observed in many experiments using independently derived stocks of recombinant virus, and at low multiplicities of infection, the inhibition of DNA synthesis was proportional to the dose of virus. Growth inhibition was still substantial 6 days after infection, although the amount of DNA synthesis increased between 2 and 6 days, presumably because the rare cells that escaped inhibition continued to proliferate and became a significant proportion of the population of cells. In a typical experiment, 2 days after infection, HeLa cells synthesized 6% as much DNA as did uninfected cells, whereas by 6 days this value had increased to 26%. The BPV E2 protein was still readily detectable by immunoprecipitation of extracts prepared from cells metabolically labeled 6 days after infection (Fig. 1B) . In contrast to the inhibitory effect on DNA synthesis, infection with Paval did not cause a significant inhibition of the incorporation of 35S-labeled amino acids into protein or cause a reduction in cell number relative to the number of cells plated (data not shown), indicating that the cells remained viable. DNA synthesis in MS751 and C-4I cells was inhibited approximately 80 and 50%, respectively, by introduction of the wild-type E2 gene, mirroring the degree of BPV E2 expression, whereas SiHa cells, which express the E2 gene poorly, were not significantly growth inhibited (data not shown). These results indicate that there was a good correlation between the level of BPV E2 expression and the inhibition of cell growth in cervical carcinoma cell lines that contain HPV DNA.
The effect of BPV E2 expression was also assessed in cells devoid of HPV DNA (Table 1) . Surprisingly, expression of the wild-type, but not mutant, E2 gene caused substantial growth inhibition of HT-3 cells, one of the prototype HPVnegative cervical carcinoma cell lines. In general, E2 expression in HT-3 cells resulted in approximately 80 to 90% inhibition of DNA synthesis. The absence of HPV DNA in HT-3 cells and the presence of a characteristic p53 mutation in these cells were confirmed as outlined in Materials and Methods. Infection of C33a cells, the other well-characterized HPV-negative cervical carcinoma cell line, had no effect on DNA synthesis or plating efficiency, but these cells did not express detectable E2 protein (data not shown). In contrast, Paval infection caused no specific growth inhibition of two noncervical cell lines, CV-1 and A431, both of which express readily detectable E2 protein following infection. Thus, the E2 protein does not exert a nonspecific growth-inhibitory effect in all epithelial cells. These results demonstrate that the growth-inhibitory effect of the BPV E2 protein is not restricted to cells expressing the HPV E6 and E7 genes but also can occur in an HPV-negative cervical carcinoma cell line.
DNA synthesis at the individual cell level was measured by autoradiography ( Fig. 5 and Table 2 ). During asynchronous growth, approximately 37% of the HeLa cells and 25% of HT-3 cells incorporated detectable label during a 5-h pulse with [3H]thymidine. These values were virtually unchanged 2 days after infection with a virus carrying the E2 nonsense mutation, whereas introduction of a wild-type E2 gene eliminated DNA synthesis in virtually all HeLa cells and in the great majority of HT-3 cells. In contrast, introduction of the E2 gene did not inhibit A431 cell DNA synthesis as measured in this assay. This autoradiographic analysis indicates that the BPV-SV40 virus induces a very large fraction of susceptible cervical carcinoma cells to undergo growth arrest and implies that biologically active E2 genes were delivered into the vast majority of cells exposed to this virus. To determine whether expression of the BPV E2 gene induced arrest at a particular stage of the cell cycle, infected HeLa and HT-3 cells were harvested, stained with propidium iodide, and subjected to flow cytometry to determine the DNA content of individual nuclei. conclusion that E2 expression in sensitive cells causes specific growth arrest and not nonspecific toxicity.
The Paval genome has the potential to express the BPV E4 and E5 proteins in addition to the proteins encoded by the E2 gene. To confirm that the BPV E2 gene was responsible for growth inhibition following Paval infection, HeLa cells were infected with a panel of viral mutants, and the effects of these mutants on DNA synthesis were determined (Fig. 7) . Substantial growth inhibition was still observed with mutants unable to express the E4, E5, or E2TR protein, demonstrating that these BPV proteins are not required for inhibition. However, the BPV-SV40 recombinant viruses express relatively low levels of the 31-kDa E2TR protein (Fig. 1) , so these experiments do not rule out the possibility that expression of high levels of this protein could also exert an inhibitory effect. In contrast, mutations that inhibited synthesis of the full-length E2 protein markedly attenuated the inhibitory effect. The modest inhibition (approximately twofold) of DNA synthesis by Pava-E2aml in the experiment shown in Fig. 7 
